

Department of Psychiatry and Neurosciences

USF Health · College of Medicine

Office of the Chair - Week of October 17 - 21, 2011

Website: <http://www.hsc.usf.edu/PSYCH/>

Newsletter

Reminder – please submit your completed annual faculty and annual staff evaluations to Maureen Tavrell by Friday, October 21st.

Meetings

- | | | | |
|----------|----------|------------|--|
| Tuesday | 10/18/11 | 12:00 noon | No Grand Rounds |
| Thursday | 10/20/11 | 8:00 a.m. | Call Center Meeting |
| | | | <u>Resident Lectures:</u> |
| | | 8:00 a.m. | PGY-3 – “Interpersonal Psychiatry”
Dr. Robert Fernandez
CHILD – “MI” Dr. Mariann Suarez |
| | | 9:00 a.m. | PGY-3 – “Clinical Case Conference”
Dr. Kailie Shaw and Elizabeth Reese, LCSW
PGY-4 – “Family Therapy”
CHILD – “MI” Dr. Mariann Suarez |
| | | 10:00 a.m. | PGY-3 & PGY-4 – “History and Introduction to Forensic Psychiatry” Dr. Isis Marrero
CHILD – Group PRITE Review |
| | | 12:00 noon | Residents’ Meeting |
| | | 1:00 p.m. | PGY-2 – “Supportive Therapy” Dr. William Upshaw |
| | | 1:00 p.m. | GERI – Journal Club |
| | | 2:00 p.m. | PGY-2 – “Consultation Liaison” Dr. Kimberly Hartney |
| Friday | 10/21/11 | | <u>Third Year Medical Student Lectures:</u> |
| | | 8:00 a.m. | “Mood Disorders” Dr. Barbara Lubrano |
| | | 10:00 a.m. | “Thought Disorders” Dr. Glenn Catalano |
| | | 1:00 p.m. | “Seizures” Drs. Benbadis/Frontera/Bozorg |
| | | 2:00 p.m. | “Sleep Disorders” Dr. Ali Bozorg |

In The Know!

Happy Birthday wishes to Brenda Curtwright/October 20th.

On October 20, 2011, from 7:00 – 9:00 p.m., The Carter-Jenkins Center will present “On Human Aggression and Youth Violence (Part II)” by Dr. Humberto Nagera, Professor Emeritus of Psychiatry at the University of Michigan and the University of South Florida; Director, The Carter-Jenkins Center, Psychoanalyst Children, Adolescents y Adultos.

Upcoming Department of Psychiatry and Neurosciences Grand Rounds

October 25, 2011, 12:00 noon to 1:00 p.m.

“Psychiatric Treatment of Deaf Youth”

Karen Goldberg, M.D., Assistant Professor, USF College of Medicine, Department of Psychiatry and Neurosciences

On November 3, 2011, at 6:30 p.m. the National Alliance on Mental Illness (NAMI) will present “Disease and Its Effect on Mental Illness” by Brian Gadbois, M.D., University of South Florida, Department of Psychiatry and Neurosciences. This program will take place at the USF Psychiatry Center, 3515 E. Fletcher Avenue, Room 232, Tampa, and is open to the public free of charge. For more information, contact 813-273-8104 or support@namihillsborough.org.

For information regarding the USF Memory Disorders Clinic, please click on the following link: http://health.usf.edu/medicine/psychiatry/p_memory_disorders_clinic.htm

Research Happenings!

Current Open Studies – Call [813-974-2832](tel:813-974-2832) or [813-974-1404](tel:813-974-1404) for more information on any study or to refer a patient.

Bipolar I Disorder with Depressive Symptoms

The Department is participating in a nationwide clinical research study evaluating the efficacy and safety of an investigational medication used as adjunctive therapy in patients with major depression associated with Bipolar I Disorder. This is a 15-week outpatient study. Patients must be 18-65 years of age and currently experiencing depressive symptoms. Patients must be on Lithium, Depakote, Lamictal, Abilify, Zyprexa, Risperdal, CONSTA, or Geodon. Assistance in obtaining Lithium and Depakote is available during the course of the study. Principal Investigator – Carlos Santana, M.D.

Schizophrenia PRIDE Study – Jail Recidivism

A 15- month open label study comparing oral antipsychotic treatment to paliperidone palmitate injections in delaying arrest recidivism in adults with Schizophrenia. Subjects must have been incarcerated at least twice in the last 24 months with the last release from jail occurring within 90 days prior to screening. Subjects receive antipsychotic medications at no charge. Principal Investigator – Jean Fils, M.D.

[NEW AUTISM STUDY](#)

We are happy to announce USF Psychiatry's participation in a Phase 4, Safety and Efficacy study of Aripiprazole in the long-term maintenance treatment of children and adolescents 6-17 years of age with irritability associated with Autistic Disorder. The study is divided into three phases - a 7-42 day screening period, a 13-26 week single-blind phase, and a 16-week double-blind, placebo-controlled phase. Kids ages 6-17 with autism are eligible to screen for this study. Call 813-974-2832 for more information. Principal Investigator - Mike Bengtson, MD.

[Now Open and Enrolling - ADHD Aggression Study](#)

Kids between the ages of 6-12 years old and in generally good health with a diagnosis of ADHD are eligible to participate in a 10-week investigational medication trial. Children must be receiving stimulant medication treatment for ADHD symptoms for 1 month prior to study enrollment and be experiencing aggressive behaviors. This study is a 10 week investigational medication trial that will test the effectiveness and safety of molindone hydrochloride extended release as an add-on treatment for aggressive behaviors in children with ADHD. Principal Investigator - Mike Bengtson, MD.

[Coming Soon - Bipolar I in Teens](#)

This study is a 3- week investigational medication trial that will test the effectiveness and safety of asenapine compared to placebo in teens ages 12-17 with Bipolar I disorder who are currently experiencing a manic or mixed episode. A 26-week extension study is available. Study medication, study visits, and required laboratory work provided at no cost. Volunteers must be between the ages of 12-17 years old and in generally good health with a diagnosis of Bipolar I disorder and currently experiencing manic or mixed symptoms. Principal Investigator - Mike Bengtson, MD.

Study-related care will include a comprehensive diagnostic exam, physical exam, laboratory testing, ECG and frequent doctor visits, as well as investigational medication, all at no charge. This is a placebo controlled trial and all participants who complete the study will have the option to enroll in an open label 6 month extension study. Enrolled patients will be compensated for time and travel.

<http://health.usf.edu/medicine/psychiatry/research/index.htm>

[Quality of Life in Youth with Tic Disorders](#)

A one-time study visit evaluating the quality of life in youth with tic disorders, specifically on various aspects of family functioning and the daily challenges faced by children and their families. Children ages 6-17 years old with a diagnosis of a tic disorder (i.e. Chronic tic disorder or Tourette Syndrome) and are experiencing current tics are eligible to participate. This study is a one-time visit that will include questionnaires and assessments. Participants will also have the opportunity to attend a focus group with youth of similar age assessing kinds of help they received and accessibility of services and the difficulties faced by having tics. Please call (727) 767-8230 for more information. Principal Investigator: Tanya Murphy, MD

Child and Adolescent Tourette's Disorder Guanfacine Clinical Trial

The purpose of this research study is to learn more about the new extended release formula of the drug, guanfacine. This new formula is called *Intuniv*. This study will help us understand how safe and how well this new extended release formula of guanfacine works for children with chronic tics. Your child is being asked to take part in this research study because he/she has been diagnosed with Chronic Motor or Vocal Tic Disorder or Tourette's Disorder. Main symptoms are motor tics such as uncontrolled movements and/or vocal tics such as repeated noises. These tics occur many times a day, nearly every day lasting for at least one year. Children ages 6-17 years old are eligible to participate.

Please call (727) 767-8230 for more information.

Principal Investigator: Tanya Murphy, MD

Living with Tics

The Living with Tics research study hopes to show how well a type of psychotherapy helps children better cope with tics and become more resilient. Children who are interested to participate must attend an initial assessment to determine eligibility. Eligible participants must be between 8 and 18 years of age, have a diagnosis of Tourette Syndrome or Chronic Tic Disorder, experience tic-related impairment, and either be medication-free or on stable medication. If eligible, interested participants will be randomly assigned to receive immediate psychotherapy or a 10 week waitlist control condition followed by subsequent psychotherapy. As part of the study, there is no charge for the psychotherapy treatment. The immediate psychotherapy condition consists of weekly therapy sessions over a 10 week period. This multi-component treatment approach includes habit reversal training, anger management, problem solving skills and other related therapeutic components to help improve the quality of life for children with chronic tic disorders.

Please call (727) 767-8230 for more information.

Principal Investigator: Eric Storch PhD

Adult OCD Ondansetron Clinical Trial

The purpose of this research study is to investigate the effectiveness, safety, and tolerability of 2 dosages Ondansetron as compared to placebo (a substance which looks like an active drug but has no active ingredient) in adult who have OCD and who are currently taking a selective serotonin reuptake inhibitor (SRI) such as Anafranil® (clomipramine) Paxil® (paroxetine), Prozac® (fluoxetine), Luvox® (fluvoxamine, or Zoloft® (sertraline). Another purpose of this study is to find out how the study drug works in the body when taken along with an SSRI.

Please call (727) 767-8230 for more information.

Principal Investigator: Tanya Murphy, MD

Pediatric OCD D-Cycloserine and Cognitive Behavioral Therapy (CBT) Research Study

The purpose of this research study is to examine if d-cycloserine enhances cognitive behavioral therapy for pediatric OCD. Participants will be involved in fifteen clinical visits spanning a nine-month period. Each participant will receive ten sessions of cognitive behavioral therapy and seven doses of the study medication or placebo one hour prior to session. Children ages 7-17 years old are eligible to participate.

Please call (727) 767-8230 for more information.

Principal Investigator: Eric Storch PhD

Cognitive-Behavioral Therapy (CBT) for Anxiety Disorders in Children with Autism Spectrum Disorder Research Study

The purpose of this research study is to examine the efficacy of a manualized cognitive-behavioral therapy to treat anxiety disorders in children with autism spectrum disorders. Therapy sessions last approximately one hour a week for sixteen weeks. In addition, participants will be involved in a number of anxiety and developmental assessments free of charge. Children ages 7-16 years old are eligible to participate.

Please call (727) 767-8230 for more information.

Principal Investigator: Eric Storch PhD